Clinical Trials Browser

Burkitt Lymphoma, Hematologic Diseases, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04121507 2023-05-24

ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

Phase 2 Completed

60 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, T-Cell

NCT05322330 2023-02-09

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Phase 2 Unknown

20 enrolled

Lymphoid

Lymphoma, B-Cell

NCT01434472 2021-07-20

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase 2 Terminated

20 enrolled 15 charts

Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

TRANSCEND FL

FIRCE-1

DALY II USA/ MB-CART2019.1 for DLBCL

ZUMA-12

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Allo HSCT Using RIC for Hematological Diseases

ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies